TITLE

A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis

AUTHOR(S)
Alton, Eric W. F. W.; Boyd, A. Christopher; Seng H. Cheng; Cunningham, Steve; Davies, Jane C.; Gill, Deborah R.; Griesenbach, Uta; Higgins, Tracy; Hyde, Stephen C.; Innes, J. Alastair; Murray, Gordon D.; Porteous, David J.
PUB. DATE
November 2013
SOURCE
Thorax;Nov2013, Vol. 68 Issue 11, p1075
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The UK Cystic Fibrosis Gene Therapy Consortium has been working towards clinical gene therapy for patients with cystic fibrosis for several years. We have recently embarked on a large, multi-dose clinical trial of a nonviral, liposome-based formulation powered for the first time to detect clinical benefit. The article describes the details of the protocol.
ACCESSION #
91663818

 

Related Articles

  • Cationic lipid-mediated gene transfer to the growing murine and human airway. JaffĂ©, A; Judd, D; Ratcliffe, C; Cheng, S H; Bush, A; Geddes, D M; Alton, E W F W // Gene Therapy;Feb2000, Vol. 7 Issue 4, p273 

    Gene therapy in patients with cystic fibrosis may need to be commenced before the onset of lung disease which may be evident as early as 4 weeks after birth. We assessed the efficacy of cationic lipid-mediated transfer of a reporter gene, chloramphenicol acetyltransferase, in the growing murine...

  • A murine tracheal culture system to investigate parameters affecting gene therapy for cystic fibrosis. Scott, E S; Goddard, C A; Wiseman, J W; Evans, M J; Colledge, W H // Gene Therapy;Apr2000, Vol. 7 Issue 7, p612 

    Cystic fibrosis (CF) is a life-threatening condition caused by mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR). Delivery of the CFTR gene to the airways offers a potential treatment for CF but requires improvement in efficiency to obtain clinical benefit. We have...

  • Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Porteous, D J; Dorin, J R; McLachlan, G; Davidson-Smith, H; Davidson, H; Stevenson, B J; Carothers, A D; Wallace, W A H; Moralee, S; Hoenes, C; Kallmeyer, G; Michaelis, U; Naujoks, K; Ho, L-P; Samways, J M; Imrie, M; Greening, A P; Innes, J A // Gene Therapy;Mar97, Vol. 4 Issue 3, p210 

    In cystic fibrosis (CF), mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene results in defective transepithelial ion transport, leading to life shortening inflammatory lung disease. Before lung studies, we tested the safety and efficacy of gene delivery to the nasal...

  • Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial. Quittner, Alexandra; Suthoff, Ellison; Rendas-Baum, Regina; Bayliss, Martha S.; Sermet-Gaudelus, Isabelle; Castiglione, Brenda; Vera-Llonch, Montserrat // Health & Quality of Life Outcomes;Jul2015, Vol. 13 Issue 1, p1 

    Background: Cystic fibrosis (CF) is an inherited, rare autosomal recessive disease that results in chronically debilitating morbidities and high premature mortality. We evaluated how ivacaftor treatment affected CF symptoms, functioning, and well-being, as measured by the Cystic Fibrosis...

  • Optimising treatment of CF pulmonary exacerbation: a tough nut to crack. Heltshe, Sonya L.; Goss, Christopher H. // Thorax;Feb2016, Vol. 71 Issue 2, p101 

    The article discusses research on the administration of hypertonic saline (HS) during hospitalisation for exacerbation of cystic fibrosis. It references a study by R. L. Dentice et al published within the issue. Topics covered include the harm or benefit of HS when used as an adjunctive therapy...

  • Getting into your genes.  // Hastings Center Report;Mar/Apr93, Vol. 23 Issue 2, p3 

    Describes the three clinical trials of somatic gene therapy for cystic fibrosis (CF) approved by the Recombinant DNA Advisory Committee. Insertion of a normal gene into lung cells; Insertion of the CF gene into nasal epithelial cells.

  • Gene therapy update. C.F. // Science World;12/3/93, Vol. 50 Issue 7, p5 

    Probes on an experimental treatment for cystic fibrosis (CF) called gene therapy. Overview of the techniques used in the therapy; Summary of test results; Safety as a major concern; Different possibilities for complications following gene therapy; Suggestions of the study.

  • Perspectives on Gene Therapy for Cystic Fibrosis Airway Disease. Bigger, B.; Coutelle, C. // BioDrugs;2001, Vol. 15 Issue 9, p615 

    Since the discovery of the cystic fibrosis transmembrane conductance regulator (CFTR) gene nearly 12 years ago, cystic fibrosis (CF) has become one of the most intensively investigated monogenetic disorders considered approachable by gene therapy. This has resulted in over 20 clinical trials...

  • Promising new therapies in works for cystic fibrosis. Starr, Cynthia // Drug Topics;8/16/93, Vol. 137 Issue 16, p14 

    Discusses development of therapies for cystic fibrosis (CF). Longer life expectancy; Improvement in life quality; CF as leading, fatal inherited disease in the United States; Explanation of disease's mechanism; Use of antibiotics; Basic molecular and genetic defect in CF; Focus on specific...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics